Is molecular profiling ready for use in clinical decision making?

Oncologist

Volumn 12, Issue 3, 2007, Pages 301-311

  Ioannidis, John P A ^a,b,c  

^a INSTITUTE OF COMPUTER SCIENCE   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Clinical practice; Clinical use; Microarrays; Molecular profiling; Prediction prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIAGNOSTIC ACCURACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; META ANALYSIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VALIDATION PROCESS;

DECISION MAKING; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 34147164024     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-3-301     Document Type: Review

References (56)

1. Lockhart DJ00, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000;405:827-836.
2. Alizadeh AA, Ross DT, Perou CM et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52.
3. Tefferi A, Bolander ME, Ansell SM et al. Primer on medical genomics. Part III: Microarray experiments and data analysis. Mayo Clin Proc 2002;77:927-940.
4. Schena M. Microarray Analysis. New York: Wiley-Liss, 2003:1-630.
5. Patsopoulos NA, Ioannidis JP, Analatos AA. Origin and funding of the most frequently cited papers in medicine: Database analysis. BMJ 2006;332:1061-1064.
6. Dalton WS, Friend SH. Cancer biomarkers-an invitation to the table. Science 2006;312:1165-1168.
7. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006;6:565-571.
8. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. The Oncologist 2006;11:541-552.
9. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856.
10. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-473.
11. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Validity of prognostic models: When is a model clinically useful? Semin Urol Oncol 2002;20:96-107.
12. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 2003;362:1439-1444.
13. Liu ET, Karuturi KR. Microarrays and clinical investigations. N Engl J Med 2004;350:1595-1597.
14. Pusztai L, Mazouni C, Anderson K et al. Molecular classification of breast cancer: Limitations and potential. The Oncologist 2006;11:868-877.
15. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ. Technology Insight: Tuning into the genetic orchestra using microarrays - limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol 2006;3:501-516.
16. Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-371.
17. Allison DB, Cui X, Page GP et al. Microarray data analysis: From disarray to consolidation and consensus. Nat Rev Genet 2006;7:55- 65.
18. Simon R, Radmacher MD, Dobbin K. Design of studies using DNA microarrays. Genet Epidemiol 2002;23:21-36.
19. Simon R, Radmacher MD, Dobbin K et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-18.
20. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-149.
21. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
22. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
23. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679.
24. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-3743.
25. Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004;104:923-932.
26. Lossos IS Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-1837.
27. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
28. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
29. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-1192.
30. Ioannidis JP. Microarrays and molecular research: Noise discovery? Lancet 2005;365:454-455.
31. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 2005;365:488-492.
32. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 2006;103:5923-5928.
33. Ein-Dor L, Kela I, Getz G et al. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 2005;21:171-178.
34. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
35. Ioannidis JPA. Gene expression profiling for individualizing breast cancer chemotherapy: success or not? Nat Clin Pract Oncol 2006;3:538-539.
36. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol 2005;58:475- 83.
37. Eden P, Ritz C, Rose C et al. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004;40:1837-1841.
38. Nimeus-Malmstrom E, Ritz C, Eden P et al. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 2006;42:2729-2737.
39. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
40. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information, Ann Intern Med 1999;130:515-524.
41. Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991;337:867-872.
42. Pan Z, Trikalinos TA, Kavvoura FK et al. Local literature bias in genetic epidemiology: An empirical evaluation of the Chinese literature. PLoS Med 2005;2:e334.
43. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180 -1184.
44. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-1055.
45. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.
46. Ioannidis JP, Pavlidis N. Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards. Eur J Cancer 2003;39:1194-1198.
47. Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003;21:2045-2047.
48. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
49. McAlister FA, Laupacis A, Wells GA et al. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-1377.
50. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 2005; 365:176-186.
51. Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006;3:540-551.
52. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
53. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-1671.
54. Staal FJ, Cario G, Cazzaniga G et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 2006;20:1385-1392.
55. Zu Y, Steinberg SM, Campo E et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk Lymphoma 2005;46:693-701.
56. Dobbin KK, Beer DG, Meyerson M et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005;11:565-572.